Community post

Hui Yue (Zhejiang University) and colleagues published a new paper on filamentous phages as tumor-targeting immunotherapeutic agents, showing engineered phages can home to tumors and block PD-1/PD-L1 interaction for targeted cancer immunotherapy without systemic side effects.